Scarica l'app Stockscreener
155.10
2.43%
3.68
Dopo l'orario di chiusura:
155.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Johnson & Johnson Invests $300.22 Billion in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity - ChartMill
Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com - Investing.com Nigeria
Protagonist Therapeutics stock hits all-time high at 155.01 USD - Investing.com
Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $5,085,176.28 in Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel Sells 65,761 Shares - MarketBeat
Protagonist Therapeutics (PTGX) CEO sells 100,000 shares after option exercise - Stock Titan
(PTGX) Risk Channels and Responsive Allocation - Stock Traders Daily
Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement (PTGX) - Seeking Alpha
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year HighHere's Why - MarketBeat
Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stock By Investing.com - Investing.com South Africa
Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says - Yahoo Finance
PTGX (PTGX) insider files to sell 225,000 shares under Rule 144 - Stock Titan
PTGX Maintained by Truist Securities -- Price Target Raised to $170 - GuruFocus
PTGX Looks 105.7% Overvalued on GF Value™ - GuruFocus
PTGX Maintained by Wedbush -- Price Target Raised to $173 - GuruFocus
Protagonist upgraded at Goldman Sachs on potential of autoimmune asset - Seeking Alpha
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $170 - Moomoo
PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118 - Bitget
Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating - Moomoo
PTGX Upgraded by Goldman Sachs -- Price Target Raised to $186 - GuruFocus
Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating - marketscreener.com
Goldman Sachs upgrades Protagonist Therapeutics stock rating on drug potential - Investing.com Australia
HC Wainwright Has Negative Forecast for PTGX FY2026 Earnings - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Rating Lowered to Buy at Wall Street Zen - MarketBeat
Protagonist Therapeutics, Inc. Just Recorded A 21% EPS Beat: Here's What Analysts Are Forecasting Next - 富途牛牛
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock - Yahoo Finance
Protagonist Therapeutics (PTGX): State Street discloses 5.2% beneficial ownership stake - Stock Titan
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175 - moomoo.com
HC Wainwright Has Negative Forecast for PTGX Q3 Earnings - MarketBeat
PTGX Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus
Bank of America Corp DE Has $136.54 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 143.43 USD By Investing.com - Investing.com UK
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $152.14, Implies 11% Upside - TradingView
Citigroup Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics stock hits all-time high at 143.43 USD - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High Following Strong Earnings - marketbeat.com
Protagonist Therapeutics2026 Funding Rounds & List of Investors - Tracxn
PROTAGONIST THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $167 FROM $117 - Bitget
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by California State Teachers Retirement System - MarketBeat
PTGX SWOT Analysis: Strong Pipeline and Strategic Collaborations Highlighted in 10-Q Filing - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates - Yahoo Finance
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics, Inc 2026: Revenue $213.48M, EPS $2.29— 10-Q Summary - TradingView
Protagonist Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q2 Revenue $213.5M, Vs. FactSet Est of $199.8M - Moomoo
Protagonist Therapeutics (NASDAQ: PTGX) jumps on $269.8M 2026 collaboration revenue - Stock Titan
Protagonist Therapeutics (NASDAQ: PTGX) turns Q2 2026 loss into profit - Stock Titan
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update - ACCESS Newswire
PROTAGONIST THERAPEUTICS, INC. : LEERINK PARTNERS RAISES TARGET PRICE TO $150.00 FROM $110.00 - Bitget
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-04 - TradingView
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: A Biotech Pioneer with Robust Revenue Growth and Promising Pipeline - DirectorsTalk Interviews
Two New Hires Get Protagonist Stock Awards Vested Over Four Years - Stock Titan
The Manufacturers Life Insurance Company Purchases 14,478 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Dimensional Fund Advisors LP Has $53.54 Million Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Segall Bryant & Hamill LLC Acquires 83,654 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Janus Henderson Group PLC Acquires 241,546 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Stempoint Capital LP - MarketBeat
Protagonist Therapeutics (PTGX) Projected to Post Earnings on Wednesday - MarketBeat
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):